FOR IMMEDIATE RELEASE • Reported net sales of $5.061 billion, representing an increase of 22.8 percent on a reported basis, compared to the company's guidance range of 17.5 to 19.5 percent; 21.6 percent on an operational basis; and 17.4 percent on an organic basis, compared to the company's guidance range of 13 to 15 percent, all compared to the prior year period. • Reported GAAP net income attributable to Boston Scientific common stockholders of$0.53 per share, compared to the company's guidance range of ...